Wegfall nationaler Regelungen bei der Umsetzung des EU Critical Medicines Act

This question concerns the removal of national regulations when implementing the EU Critical Medicines Act. It seeks clarification on how this harmonization will affect existing German rules and ensure compliance with EU standards. The focus is on the impact on national pharmaceutical policies and the potential for streamlined processes. It addresses concerns about maintaining regulatory oversight while adopting EU-wide measures for critical medicines.